Orphan drug launches reach 10-year high in 2011
Orphan drug launches for rare diseases reached a 10-year high in 2011, underscored by new breakthroughs in personalized medicine, according to a report by IMS Institute for Healthcare Informatics in New Jersey. Orphan drugs carry a higher price tag than other drugs because they are intended for a patient population of no more than 200,000. […]